Nicardipine

Nicardipine
Clinical data
Trade names	Cardene
AHFS/Drugs.com	Monograph
MedlinePlus	a695032
Routes of; administration	Oral, intravenous
ATC code	C08CA04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	>95%
Elimination half-life	8.6 hours
Identifiers
	IUPAC name 2-[benzyl(methyl)amino]ethylmethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	55985-32-5 ;
PubChem CID	4474;
IUPHAR/BPS	2559;
DrugBank	DB00622 ;
ChemSpider	4319 ;
UNII	CZ5312222S;
KEGG	D08270 ;
ChEMBL	ChEMBL1484 ;
CompTox Dashboard (EPA)	DTXSID6023363 ;
ECHA InfoCard	100.054.466
Chemical and physical data
Formula	C26H29N3O6
Molar mass	479.533 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	136–138 °C (277–280 °F)
	SMILES O=C(OCCN(Cc1ccccc1)C)\C2=C(\N/C(=C(/C(=O)OC)C2c3cccc([N+]([O-])=O)c3)C)C;
	InChI InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3 ; Key:ZBBHBTPTTSWHBA-UHFFFAOYSA-N ;
	(verify)

Nicardipine (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the dihydropyridine class of calcium channel blockers. It is also used for Raynaud's phenomenon. It is available in by mouth and intravenous formulations. It has been used in percutaneous coronary intervention.[1]

Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[2]

It was patented in 1973 and approved for medical use in 1981.[3]

References

Huang RI, Patel P, Walinsky P, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheter Cardiovasc Interv. 68 (5): 671–6. doi:10.1002/ccd.20885. PMID 17034064.
Nicardipine at Medline PLus
Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid17034064-1] Huang RI, Patel P, Walinsky P, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheter Cardiovasc Interv. 68 (5): 671–6. doi:10.1002/ccd.20885. PMID 17034064.

[2] Nicardipine at Medline PLus

[3] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495.